lobbying_activities: 1661465

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1661465	e1ee4242-67a7-4a55-bb8c-71e41c2cc99d	Q1	GSK (FKA GLAXOSMITHKLINE INC.)	16293	GSK (FKA GLAXOSMITHKLINE INC.)	2015	first_quarter	CPT	H.R. 9 - Innovation Act, provisions related to patent litigation reform S. 131 - Fair and Immediate Release of Generic Drugs Act, provisions related to patent settlements S. 632 - STRONG Patents Act of 2015, provisions relating to post grant proceedings, bad faith demand letters, and PTO diversion No bill # assigned - Biopharmaceutical innovation policy issues No bill # assigned - Biologics data protection issues No bill # assigned - Intellectual property issues, additional data exclusivity request that was part of 21st Century Cures submission	HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR)		1730000	0	0	2015-04-15T10:45:31.960000-04:00